Halogenated inhalational anesthetics, which have been used for the induction and maintenance of general anesthesia, can cause liver injury, ranging from temporary transaminase elevation to hepatic necrosis. It is rare but causes serious morbidity and mortality. Herein we present a case of severe transaminase elevation after using desflurane anesthesia for obesity surgery.
I nhalational anesthetics are the most commonly used agents for the induction and maintenance of general anesthesia [1] . Halothane, enflurane, isoflurane, desflurane, and sevoflurane are well-known inhalational anesthetics. Drug-induced liver injury, which may develop after using inhalational anesthetics, can range from asymptomatic transaminase elevations to fatal hepatic necrosis [2] . Hepatotoxicity after halothane inhalation is a common occurrence and has been extensively studied. However, fewer cases of hepatotoxicity have been reported for the newest agents such as desflurane and sevoflurane. Here, we present a case of severe transaminase elevations after desflurane anesthesia.
Case Report
A 47-year-old woman with a complaint of morbid obesity was admitted to our hospital for obesity surgery. She had a history of diabetes mellitus and depression and had a history of metformin and duloxetine administration. She was surgery-naive and had no history of jaundice, blood transfusions, or alcohol use. She was immunized against hepatitis B. Preoperative laboratory study findings are summarized in Table 1 . The patient underwent sleeve gastrectomy under general anesthesia using fentanyl, propofol, N 2 O, and desflurane. The patient remained hemodynamically stable throughout the surgery and no blood products were administered. Twenty-four hours following surgery, the patient suffered from subfebrile fever and nausea and her laboratory test findings showed markedly elevated aminotransferase levels but no evidence of hyperbilirubinemia or coagulopathy. Clinical and laboratory parameters were monitored ( Table 1) . Her hepatitis and human immunodeficiency virus serology findings were negative for acute infection, and serology findings for hepatitis B surface antibody and hepatitis A immunoglobulin G were positive. Her Epstein barr virus and cytomegalovirus serology findings were negative. Antinuclear antibody and anti-smooth muscle antibody screens were also negative. Iron panel findings were in the normal range. Other serological values included the following: ceruloplasmin, 30 mg/dl (normal, 18-36 mg/dl) and serum copper 87 mg/dl (normal, 70-155 mg/dl). Her electrolyte values were within the normal range and she had no clinical or laboratory signs of sepsis. An ultrasound of the liver and gallbladder was unremarkable and there was no evidence of ascites. The decision was made to continue conservative management. There was gradual clinical improvement and her laboratory values completely normalized seven days following the surgery as seen in Figure 1 .
Discussion
For more than 50 years, halogenated inhalational anesthetics have been used for general anesthesia and their use is reportedly associated with liver injury [1] . Risk factors include obesity, female sex, middle age, and multiple anesthetics over a short period of time [4] . Obesity, female sex, and middle age were present in our patient as risk factors.
In approximately 20% of patients who were repeatedly administered halothane anesthesia, a mild hepatitis with low-grade fever, nausea, and a mild transient elevation of liver enzymes was observed. In contrast, a fulminant hepatitis occurred in 1 in 20.000 patients exposed to halothane and was characterized by jaundice, hepatomegaly, hepatic encephalopathy, and markedly increased liver enzymes [5] . However, halothane is no longer used in many developed countries as in our country. Fortunately, fewer cases of hepatotoxicity have been reported for the newest agents [6] . Most hypotheses on the mechanism of halogenated anesthetics induced hepatic injury are based on the production of metabolites causing immunoallergic reaction in patients [7] . Enflurane, isoflurane, and desflurane metabolized and produced hepatotoxic proteins, containing trifluoroacety- [3] . In contrast with other halogenated anesthetics, sevoflurane metabolism did not result in the formation of TFA, suggesting that evoflurane has a low hepatotoxic potential [1] . Nevertheless, autoantigen-specific IgG4 antibodies have reportedly been associated with hepatotoxicity [8] . The occurrence of hepatic injury following desflurane anesthesia was once believed to be rare. However, reports of complications associated with the use of this anesthetic continue to be accumulated. Generally, treatment of hepatotoxicity and hepatitis caused by halogenated anesthetics are supportive care and medical follow up [9] . In addition, some case reports show the benefit of glucocorticoids in the literature [10] . In the setting of acute liver failure, the case fatality rate can be as high as 80% in those who develop hepatic encephalopathy. Severe, progressive cases may require emergent liver transplantation. Fortunately, in our patient, with close laboratory monitoring and supportive care completely normalized laboratory parameters and clinical improvement within one week were observed.
Even though anesthesia-induced liver injury is not a common occurrence, we should be aware of the association of the disease with the use of halogenated anesthetics.
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